Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bid to Find New Drugs Against TB Using Genomics (Singapore)

This article was originally published in PharmAsia News

Executive Summary

Forty representatives from some of the world's top research institutions met in Singapore for a conference called Grand Challenges in Global Health: Drugs for Latent Tuberculosis. As its name suggests, Grand Challenges was designed to discuss new solutions for combating tuberculosis around the world. The two-day conference began on Oct. 24 in Singapore's Biopolis, located in the city-state's North Buona Vista area. Participants included researchers from the United States, Britain, Mexico, South Korea, and the Novartis Institute of Tropical Diseases in Singapore. The major focus of Grand Challenges was the possible use of genomics to develop a more effective tuberculosis treatment. Theoretically, scientists would disable different molecules of a drug to better analyze how each one operates to fight the disease. The goal of the group is to develop a treatment that would eliminate tuberculosis in under two-weeks. The current treatment time is nine months, however, a new drug with a two-month treatment window is already in Phase III trials. (Click here for more - May Require Paid Subscription

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts